Welcome to the PEER Network.

Get lifestyle support and practical insights from patients who have walked the same journey.

CONNECT WITH APEER Mentoror CONTINUE YOURConversation

PEER Mentors are here for you

Whether you have already started therapy or are still considering your options for pulmonary arterial hypertension treatment, the PEER Network is here for you. PEER Mentors are available to share practical information and answer your lifestyle questions associated with your treatment. PEER Mentors are patients and caregivers who have personal experience with one of these medications:

  • Orenitram® (treprostinil) Extended-Release Tablets
  • Tyvaso® (treprostinil) Inhalation Solution
  • Remodulin® (treprostinil) Injection

Meet a few of our Mentors

Search for and connect with a Mentor today
Log in to continue your conversation with your Mentor

The PEER Network is sponsored exclusively by United Therapeutics Corporation. This information is provided for an informational purpose and is not intended as treatment advice. Patients should consult a healthcare professional for treatment advice.

About Us

The PEER Network is a resource for patients, and their caregivers, who are considering or initiating Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. United Therapeutics Corporation established the PEER Network in May 2007 to provide support for those with pulmonary arterial hypertension (PAH).

The PEER Network connects patients who are considering or initiating one of these medications with patients who have experienced the challenges of incorporating the same medication into their daily routine. Through the program, new patients (called “Mentees”) can receive emotional support and practical insight from experienced patients (called “Mentors”). By connecting Mentees to Mentors who have walked a similar path, Mentees can gain confidence and encouragement along their own journey.

Who can be a Mentee?

Those people who wish to connect with a Mentor are referred to as Mentees. Mentees are typically PAH patients or caregivers who are considering or have recently started taking Orenitram, Tyvaso, or Remodulin. Mentees can also include those who want to know more about what it's like to take those therapies or those seeking practical and emotional support.

The PEER Network allows for Mentors and Mentees to correspond by exchanging e-mails through a secure website or by having a private phone conversation.

Why connect with a Mentor?

Those who may benefit from speaking with a Mentor include anyone who is

  • Considering or initiating Orenitram, Tyvaso, or Remodulin therapy
  • Switching from one route of administration of Remodulin to another
  • Providing care to someone who is considering or initiating treatment with Orenitram, Tyvaso, or Remodulin

The PEER Network is sponsored exclusively by United Therapeutics Corporation and managed by Health Advocacy Strategies™ (H.A.S.), a health communications company in Seattle, Washington. H.A.S. staffs the PEER Network and other similar programs that help empower people. H.A.S. staff members are not employees of United Therapeutics Corporation.

If you are interested in learning more about how the PEER Network program works, please see the FAQs. For more information, you may contact the PEER Network at info@peernetwork.net or call 1-866-505-7337.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Frequently Asked Questions (FAQs)

  1. PEER Network Basics
    What is the PEER Network?
    The PEER Network is a resource for patients, and their caregivers, who are considering or initiating Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. United Therapeutics Corporation established the PEER Network in May 2007 to provide support for people with pulmonary arterial hypertension (PAH). The PEER Network connects patients who are considering or initiating a medication with patients who have experienced the challenges of incorporating the same medication into their daily routine. Through the program, new patients (called "Mentees") can receive emotional support and practical insight from experienced patients (called "Mentors"). By connecting Mentees to Mentors who have walked a similar path, Mentees can gain confidence and encouragement along their own journey.
    Who are PEER Mentors?
    PEER Mentors are volunteer patients, or their caregivers, who are receiving either Orenitram, Tyvaso, or Remodulin for WHO Group 1 pulmonary arterial hypertension (PAH) and are willing to help other patients who are considering or initiating the same medication. Mentors provide firsthand knowledge and insights on practical and lifestyle considerations associated with treatment.
    How does the PEER Network operate?
    PEER Mentors exchange confidential e-mails with their Mentees through a secure website. These messages cannot be viewed by anyone other than the Mentor and Mentee. Mentors will be available to share their personal experiences managing the practicalities of Orenitram, Tyvaso, or Remodulin. Mentors do not offer medical advice and will refer all Mentees to their doctors for answers to medical questions.
    Who benefits from the PEER Network?
    The PEER Network has been developed to support pulmonary arterial hypertension (PAH) patients 18 and over, and their caregivers who are considering or initiating treatment with Orenitram, Tyvaso, or Remodulin.
    Is the PEER Network open to non-US citizens?
    The PEER Network is intended for US audiences only. This PEER Network program and website are sponsored by United Therapeutics Corporation. Program participation, product copy, and claims are intended only for residents of the United States. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram, Tyvaso, or Remodulin.
  2. Registration
    What are the steps required to connect with a PEER Mentor?

    • Go to www.peernetwork.net
    • Click on the Connect With a Mentor link on the home page
    • Indicate whether you wish to communicate with an Orenitram, Tyvaso, or Remodulin Mentor
    • Choose how you would like to communicate with a PEER Mentor (e-mail or phone)

    If e-mail communication is preferred:

    • Select the e-mail option
    • Review all the Mentor options listed or use the Narrow your Mentor search function
    • Choose one Mentor with whom you would like to communicate
    • Click on Contact Me to connect with your Mentor
    • Fill out the e-mail registration form and submit the form electronically
    • E-mail your new Mentor through a secure e-mail interface
      Note: You will receive a confirmation e-mail that you have registered for the program. The program may require you to log in with your username and password before you e-mail your new Mentor.

    If phone communication is preferred:

    • Select the phone option
    • Fill out a phone registration form
    • Submit the form electronically
    • PEER Network staff will contact you and arrange a phone conversation with a Mentor
    Can I change my PEER Mentor after registering?
    Yes. If for any reason you would like to connect with a different Mentor, please contact the PEER Network by e-mailing info@peernetwork.net or calling 1-866-505-7337. PEER Network staff will deactivate your current Mentor relationship and help you re-register and choose a new Mentor.
  3. Communicating With PEER Mentors
    How do PEER Mentors communicate with pulmonary arterial hypertension patients and/or caregivers?

    After registering at www.peernetwork.net, patients are directed to a private and secure e-mail interface. The PEER Network enables patients to exchange confidential e-mails with the PEER Mentor of their choice over a secure Web-based system. All information is stored on a password-protected server.

    If a patient does not have access to e-mail or prefers to speak to a Mentor over the phone, they may register to connect with a Mentor via phone instead of communicating via e-mail.

    Does it cost anything for patients and/or caregivers to sign up to communicate with a PEER Mentor?

    No. There is no charge to communicate with a PEER Mentor.

    How long can I communicate with my PEER Mentor?

    Most Mentor/Mentee connections last approximately four to six weeks. Program rules allow for a maximum communication period of four months between you and your Mentor. After four months, if you would still like to connect with a Mentor, you may contact the PEER Network to select a new Mentor or see if your previous Mentor is still available.

    Can I communicate with more than one PEER Mentor at a time?

    No. You will only be able to communicate with one PEER Mentor at any given time. If you would like to change your Mentor, please contact the PEER Network at info@peernetwork.net or call 1-866-505-7337. PEER Network staff will deactivate your current Mentor relationship and help you re-register and choose a new Mentor.

    What if I don’t receive a response from my PEER Mentor within 48 hours of registration?

    Please know that the PEER Mentors are volunteers and may not be checking their e-mail every day. However, if you do not receive a response from your Mentor within 48 hours of registration, please e-mail the PEER Network at info@peernetwork.net or call 1-866-505-7337. PEER Network staff will look into the delay and, if necessary, connect you with a new Mentor.

    What if I don’t have e-mail?
    If you do not have e-mail, you may speak with a PEER Mentor over the phone. Complete the phone registration form and the PEER Network staff will search for a Mentor who will best suit your needs. PEER Network staff will contact the Mentor to be sure he/she is available to talk to you and arrange for a toll-free call. Network staff will follow up with you after the call to be sure you were satisfied with your Mentor experience.
    Can I speak with a Mentor over the phone?
    Yes. The phone option allows for you to have a conversation with a PEER Mentor over the phone. As soon as the phone registration form that you fill out is received, PEER Network staff will search for a Mentor who will best suit your needs. PEER Network staff will contact the Mentor to be sure he/she is available to talk to you and arrange the call. PEER Network staff will follow up with you after the call to be sure you were satisfied with your Mentor experience. To protect privacy, your phone number is not given to your Mentor. You will be connected via a privacy-protected toll-free conference line.
  4. Mentors
    How are PEER Mentors recruited?

    PEER Mentors are primarily identified through physician offices. Healthcare providers share information about the PEER Network with their patients and refer them to the program. Healthcare providers may receive a packet that includes patient invitation letters and PEER Network Interest Forms, which they will distribute to their patients who may be interested in becoming Mentors. The PEER Network staff will follow up via phone to further explain the program and to hear more about the patient’s personal experience with pulmonary arterial hypertension.

    Are PEER Mentors paid?

    No. PEER Mentors volunteer to help others who are considering the same medication. They do not receive compensation for their time.

    How can I become a PEER Mentor?

    Volunteer PEER Mentors must be diagnosed with PAH (WHO Group I) and have been on Orenitram, Tyvaso, or Remodulin for an approved indication for at least four months, or be the caregiver of such a patient.

    If you meet this description, and you would like to help other patients and/or caregivers, please call 1-866-505-7337, fill out a Release Form, or contact the PEER Network via e-mail at info@peernetwork.net for more information.

  5. Opt Out of PEER Network
    Can I opt out of the program after registering?

    Yes. You can opt out of the program at any time. All PEER Network e-mails sent to you after registering include an opt-out option. You can also e-mail the Network at info@peernetwork.net or call 1-866-505-7337 at any time to opt out.

  6. Privacy
    How will the information that I fill out on the registration page be used?

    Mentees provide basic contact and demographic information when registering. Your personal information is not used, sold, or assigned for any purpose other than to communicate with you about the PEER Network program and as otherwise required by law. Please see the PEER Network website Privacy Policy for full information.

    Can I see a history of my messages after my four months are up?

    No. In support of our commitment to your privacy, all of the e-mails between you and your Mentor will be deleted four months after you register for the PEER Network program, or sooner if participation is discontinued.

    Will my conversations with my PEER Mentor be private?

    Yes. After registering, you will be directed to a secure, online e-mail interface where you can exchange private e-mails with your PEER Mentor. E-mail exchanges are not monitored or viewed by anyone other than you and your Mentor and all information is stored on a password-protected server. If you choose to speak with your Mentor via phone, the conversation will be private.

  7. Therapies and PEER Network Sponsors
    Who sponsors and manages the PEER Network?

    The PEER Network is sponsored exclusively by United Therapeutics Corporation. It is managed by Health Advocacy Strategies™ (H.A.S.), a health communications company in Seattle, Washington. H.A.S. staffs the PEER Network and other similar programs. H.A.S. staff members are not employees of United Therapeutics Corporation.

    What is Orenitram® (treprostinil) Extended-Release Tablets?

    Indication

    Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.

    Important Safety Information for Orenitram

    Do not take Orenitram if you have severe liver problems.

    Before you take Orenitram, tell your healthcare provider if you:
    • Have liver problems, diverticulosis, or any other medical conditions
    • Are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. You and your healthcare provider should decide if you will take Orenitram or breastfeed. You should not do both

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.

    Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.

    If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.

    Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.

    The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.

    OREISIdtcJAN16

    Please see accompanying Full Prescribing Information and Patient Information for Orenitram.

    For additional information about Orenitram visit http://www.Orenitram.com or call 1-877-UNITHER (1-877-864-8437).

    What is Tyvaso® (treprostinil) Inhalation Solution?

    Indication

    Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

    The effects of Tyvaso are unknown in patients under 18 years of age.

    Important Safety Information for Tyvaso

    • Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.

    Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

    • Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
    • Have a lung infection.
    • Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
    • Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
    • Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
    • Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.

    It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

    • Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners (anticoagulants).
    • Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your risk for hypotension (low blood pressure).
    • Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or Rifater (for infection), as your Tyvaso dosage may need adjustment.

    The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

    TYVISIdtcJUN16

    Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.

    For additional information about Tyvaso, visit www.tyvaso.com or call 1-877-UNITHER (1-877-864-8437).

    What is Remodulin® (treprostinil) Injection?

    Indication

    Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

    In people with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

    Important Safety Information for Remodulin

    • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
    • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
    • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
    • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
    • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
    • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
    • Because Remodulin can reduce the blood’s ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
    • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
    • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).

    For additional information about Remodulin, please see the Full Prescribing information, visit http://www.remodulin.com, or call 1-877-UNITHER (1-877-864-8437).

    What is Living PAH?
    Living PAH can connect you to a growing community of support designed to help you get the most from your care. Living PAH is a place where patients and caregivers can find support, resources, disease education, and treatment information to help them find the path that is right for them. There is no charge for any of the Living PAH resources, which can be accessed on-line or via the call center at 1-877-948-9137. You can sign up to receive e-newsletters and notices about new programs and events in your area. Visit LivingPAH.com to enroll.
  8. Other Resources
    What are other resources I can access?

    Living PAH can connect you to a growing community of support designed to help you get the most from your care. Living PAH is a place where patients and caregivers can find support, resources, disease education, and treatment information to help them find the path that is right for them. There is no charge for any of the Living PAH resources, which can be accessed on-line or via the call center at 1-877-948-9137. You can also sign up to receive e-newsletters and notices about new programs and events in your area. Visit LivingPAH.com to enroll.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Resources for your PAH Journey

The PEER Network is dedicated to providing you with practical information and emotional support as you consider or begin treatment with a United Therapeutics Corporation therapy. Many other resources are available to help you with your disease and treatment journey. Below is a list of resources to help get you started.

Living PAH – Living PAH can connect you to a growing community of support designed to help you get the most from your care. Living PAH is a place where patients and caregivers can find support, resources, disease education, and treatment information to help them find the path that is right for them. There is no charge for any of the Living PAH resources, which can be accessed on-line or via the call center at 1-877-948-9137. You can also sign up to receive e-newsletters and notices about new programs and events in your area. Visit LivingPAH.com to enroll.

Pulmonary Hypertension Association – PHA’s mission is to find ways to prevent and cure pulmonary hypertension and to provide hope for the PAH community through support, education, advocacy, and awareness.

United Therapeutics Corporation – United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. For more information, call the United Therapeutics Corporation at 1-877-UNITHER (1-877-864-8437).

Orenitram.com – Learn more about Orenitram® (treprostinil) Extended-Release Tablets and find Full Prescribing Information.

Tyvaso.com – Learn more about Tyvaso® (treprostinil) Inhalation Solution and find Full Prescribing Information.

Remodulin.com – Learn more about Remodulin® (treprostinil) Injection and find Full Prescribing Information.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

  • Step 1: Search for a Mentor
  • Step 2: Choose Your Mentor
  • Step 3: Register
  • Step 4: Get Started
  • Step 1: Search for a Mentor
  • Step 2: Register
  • Step 3: Thank You

Step 1: Search for a Mentor

If you are considering or currently taking a United Therapeutics Corporation treatment for PAH, you are invited to connect with a PEER Mentor.

I want to connect with a PEER Mentor taking

I would like to connect with my Mentor by


You may opt out of the PEER Network program at any time, for any reason. All PEER Network e-mails sent to you after registering include an opt-out option. You can also e-mail the Network at info@peernetwork.net or call
1-866-505-7337 at any time to opt out.

Step 2: Choose Your Mentor

Narrow your Mentor search

Please contact the PEER Network toll-free at 1-866-505-7337 or via e-mail at info@peernetwork.net so that we can contact you as soon as an Orenitram Mentor becomes available.

Please contact the PEER Network toll-free at 1-866-505-7337 or via e-mail at info@peernetwork.net so that we can contact you as soon as a Mentor becomes available.

PeerNetwork

Born in:
Location:
Administration:
Diagnosed:
Background:
PeerNetwork

Born In:
Location:
Diagnosed:
Background:

Step 2: Register

Thank you for your interest in the PEER Network.
Here are the next steps for connecting with your Mentor.

  1. Complete and submit the registration form below.
  2. A PEER Network staff member will contact you to arrange the call with your PEER Mentor.
  3. Your PEER Mentor will call you at the designated time via a privacy-protected conference line.

Step 3: Register

Thank you for your interest in the PEER Network.
To connect with your Mentor, please complete and submit the registration form below.

Mentor Profile Image

Born in:
Location:
Administration:
Diagnosed:
Background:

Born in:
Location:
Diagnosed:
Background:

Complete Registration Form

Please note that the information you provide below will be used only for this program and will remain confidential in accordance with United Therapeutics Corporation's Privacy Policy.

* Required field

Account Information

Remember your password!

You will need it to log in to communicate with your Mentor.

Personal Information
Get Started Now

If you have any questions, please don't hesitate to contact the PEER Network staff at info@peernetwork.net or 1-866-505-7337.
If you wish to opt-out of the PEER Network Program, please e-mail us at info@peernetwork.net or call 1-866-505-7337.

Thank you for registering

A PEER Network staff member will contact you by phone within 48 hours
to arrange a convenient time to speak with a Mentor.

You will then be connected to your new Mentor by phone. Thank you for registering.

If you have any questions, please don't hesitate to contact the PEER Network staff at info@peernetwork.net or 1-866-505-7337.
If you wish to opt-out of the PEER Network Program, please e-mail us at info@peernetwork.net or call 1-866-505-7337.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Become a PEER Mentor

We are always looking for patients with pulmonary arterial hypertension (PAH) or caregivers who are interested in becoming PEER Mentors. If you have experience with Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection, you may be eligible to be a PEER Mentor.

The PEER Network is a resource for patients, and their caregivers, who are considering or initiating Orenitram, Tyvaso, or Remodulin therapy. The PEER Network connects patients who have experience taking these medications with patients who are considering or initiating the same medication. These new patients (called “Mentees”) receive emotional and practical lifestyle support from experienced patients (called “Mentors”). By connecting with a PEER Mentor, Mentees can gain a patient’s perspective on lifestyle considerations associated with taking the medication and fitting treatment into their daily routine.

PEER Mentors volunteer their time to share their personal experiences with the practical and lifestyle considerations associated with their treatment decisions. Mentors provide emotional support and encouragement for others who are facing similar treatment decisions.

To become a PEER Network Mentor, you must meet the following requirements:

  1. Patient must have at least 4 months of experience on a specific United Therapeutics Corporation therapy and have their diagnosis and treatment information verified by their PAH prescribing physician
  2. Patient must complete a 30- to 45-minute assessment interview with PEER Network staff
  3. Patient must complete Mentor training, pass the training quiz, and then complete re-training and re-certification each year to stay in the program
  4. Mentor must be willing to receive phone and/or e-mail updates from the PEER Network and respond to Mentee e-mails and phone calls within 48 hours during the four-month communication period with a Mentee

To learn more about becoming a PEER Network Mentor, please complete the form below and a member of the PEER Network staff will contact you to share more information.

You can also contact the PEER Network directly via e-mail at info@peernetwork.net or by phone at 1-866-505-7337.

If the above requirements describe you and you would like to be a PEER Mentor, please complete the Network Release Form and return it via mail, e-mail, or fax as indicated on the form. You may also call us toll-free at 1-866-505-7337 or e-mail info@peernetwork.net for more information. By signing and returning this form, you have provided your permission for the PEER Network staff to contact you.

Yes! I would like to become a PEER Mentor

* Required fields

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Contact Us

There are several ways to contact the PEER Network:

E-mail:
info@peernetwork.net
Toll-free by phone:
1-866-505-7337
Fax:
1-877-733-7202
Mail:
PEER Network, PMB 227, 4111 E. Madison St., Suite 2, Seattle, WA 98112-9944

Our standard business hours are 8 AM to 5 PM (Pacific Standard Time) Monday through Friday. If you call and leave a message outside of our normal operating hours, we will get back to you the next business day.

THE PEER NETWORK IS INTENDED FOR US AUDIENCES ONLY. If you are located outside of the United States, please consult with your local physician or pharmacy for information about Orenitram® (treprostinil) Extended-Release Tablets, Tyvaso® (treprostinil) Inhalation Solution, or Remodulin® (treprostinil) Injection. The Full Prescribing Information for these products is listed below.

Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Orenitram® (treprostinil) Extended-Release Tablets

INDICATION

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram may improve your ability to exercise. It is not known if Orenitram is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION for Orenitram

Do not take Orenitram if you have severe liver problems.

Before you take Orenitram, tell your healthcare provider if you:

  • Have liver problems, diverticulosis, or any other medical conditions
  • Are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. You and your healthcare provider should decide if you will take Orenitram or breastfeed. You should not do both

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start or stop any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains the same ingredient, treprostinil. Know the medicines you take. Keep a list of them and the dose you take to show to your healthcare provider and pharmacist when you get a new medicine.

Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider. Stopping Orenitram suddenly may cause worsening of your PAH symptoms. If you miss two or more doses of Orenitram, call your healthcare provider. If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.

If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. Take Orenitram with food.

Orenitram can cause serious side effects, including an increased risk of bleeding. This risk could be increased if you are taking blood thinners such as warfarin.

The most common side effects of Orenitram include headache, diarrhea, nausea and flushing. These are not all of the possible side effects of Orenitram. Tell your doctor about any side effects that bother you, get worse over time, or do not go away.

OREISIdtcJAN16

Please see the Full Prescribing information and Patient Information for Orenitram.

For more information about Orenitram, visit www.orenitram.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Tyvaso® (treprostinil) Inhalation Solution

INDICATION

Tyvaso is a prescription medicine used in adults to treat pulmonary arterial hypertension (PAH) (WHO Group 1), which is high blood pressure in the arteries of your lungs. Tyvaso can improve exercise ability in people who also take bosentan (an endothelin receptor antagonist, (ERA)) or sildenafil (a phosphodiesterase-5 (PDE-5) inhibitor). Your ability to do exercise decreases 4 hours after taking Tyvaso.

The effects of Tyvaso are unknown in patients under 18 years of age.

IMPORTANT SAFETY INFORMATION for Tyvaso

  • Tyvaso is breathed in (inhalable) through your mouth into your lungs. Tyvaso should only be used with the Tyvaso Inhalation System.

Before you take Tyvaso, tell your healthcare provider about all of your medical conditions, including if you:

  • Have a lung disease (such as asthma or chronic obstructive pulmonary disease (COPD)).
  • Have a lung infection.
  • Have liver or kidney problems, as your ability to tolerate Tyvaso may be affected.
  • Have low blood pressure, as Tyvaso may cause symptomatic hypotension (low blood pressure).
  • Are pregnant or plan to become pregnant. It is not known if Tyvaso will harm your unborn baby. Women who can become pregnant should use effective birth control while taking Tyvaso.
  • Are breast-feeding or plan to breast-feed. It is not known if Tyvaso passes into your breast milk.

It is important to tell your healthcare provider about all the medicines you may be taking, including prescription and non-prescription medicines, vitamins, and herbal supplements, as they may affect your use of Tyvaso by increasing the risk of side effects or decreasing effectiveness. Especially tell your healthcare provider if you take any of these medicines:

  • Medicines that decrease blood clotting such as warfarin or heparin, as Tyvaso reduces the ability of your blood to clot (coagulate), and increases your risk for bleeding if you are taking blood thinners (anticoagulants).
  • Diuretics (water pills), antihypertensives (medications used to treat high blood pressure or heart disease), or other vasodilators (medications that lower blood pressure), as Tyvaso may increase your risk for hypotension (low blood pressure).
  • Gemfibrozil such as Lopid (for high cholesterol) or rifampin such as Rimactane, Rifadin, Rifamate or Rifater (for infection), as your Tyvaso dosage may need adjustment.

The most common side effects of Tyvaso are coughing, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), and fainting or loss of consciousness. These are not all the possible side effects of Tyvaso. Tell your healthcare provider about any side effects that bother you or do not go away. Your healthcare provider may be able to help you manage the side effects.

TYVISIdtcJUN16

Please see the Full Prescribing Information, Patient Package Insert, and Tyvaso Inhalation System Instructions for Use Manual.

For more information about Tyvaso, visit www.tyvaso.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Remodulin® (treprostinil) Injection

INDICATION

Remodulin is a prescription medication used in adults with pulmonary arterial hypertension (PAH; WHO Group 1), to diminish symptoms associated with exercise. PAH is high blood pressure in the arteries of your lungs. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. Remodulin is delivered (infused) continuously using a pump connected to a small tube that is either placed under the skin (subcutaneously [SC]) or inserted into a vein in the upper chest (intravenously [IV]). Because there are risks associated with continuous IV infusion, such as serious blood stream infections, IV infusion should be reserved for people who cannot tolerate SC infusion or for those in whom the risks are considered acceptable.

In patients with PAH who need to switch from Flolan® (epoprostenol sodium), Remodulin is approved to slow the worsening of symptoms. The risks and benefits of each drug should be carefully considered before switching.

IMPORTANT SAFETY INFORMATION for Remodulin

  • Continuous intravenous (IV) infusions of Remodulin are delivered using a tube placed in a central vein within the chest. This type of delivery is associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
  • You should not stop or greatly reduce your Remodulin dose without consulting your doctor, as this may cause your PAH symptoms to worsen.
  • Other medical conditions and medicines may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug's effectiveness. It is important to tell your doctor about your medical conditions and any medicines you may be taking.
  • If you have liver or kidney problems, your ability to tolerate Remodulin may be affected.
  • If you are taking gemfibrozil (for high cholesterol), rifampin (for infection), or other drugs that affect liver enzymes, your doctor may need to adjust your Remodulin dosage.
  • Remodulin acts by lowering your blood pressure. In some cases your blood pressure may become too low and cause other side effects. If you also take other drugs that lower your blood pressure, the risk is increased. You should discuss all of your symptoms with your doctor, including those associated with low blood pressure.
  • Because Remodulin can reduce the blood's ability to clot, it may increase your risk of bleeding, especially if you are taking anticoagulants (blood thinners).
  • If you are pregnant, breast-feeding, or planning to become pregnant, talk with your doctor about whether you should take Remodulin.
  • Side Effects: In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness and swelling). These symptoms were often severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain. Other common side effects seen with either SC or IV Remodulin were headache, diarrhea, jaw pain, nausea, vasodilatation (widening of the blood vessels), and edema (swelling).

Please see the Full Prescribing Information for Remodulin.

For more information about Remodulin, visit www.remodulin.com. Questions? Call 1-877-UNITHER (1-877-864-8437).

Orenitram, Tyvaso, and Remodulin are registered trademarks of United Therapeutics Corporation.

All other brands are trademarks of their respective owners. The makers of these brands are not affiliated with and do not endorse United Therapeutics or its products.